128,400 Shares in Absci Co. (NASDAQ:ABSI) Acquired by Jump Financial LLC

Jump Financial LLC acquired a new stake in Absci Co. (NASDAQ:ABSI - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 128,400 shares of the company's stock, valued at approximately $336,000. Jump Financial LLC owned about 0.11% of Absci at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ABSI. PCA Investment Advisory Services Inc. acquired a new position in shares of Absci during the 4th quarter worth about $26,000. Alpha Cubed Investments LLC bought a new position in Absci in the 4th quarter worth approximately $26,000. Ballentine Partners LLC bought a new stake in shares of Absci in the fourth quarter valued at approximately $27,000. Verdence Capital Advisors LLC acquired a new stake in shares of Absci in the fourth quarter worth $37,000. Finally, Mariner LLC bought a new position in Absci during the fourth quarter worth $62,000. Institutional investors and hedge funds own 52.05% of the company's stock.

Absci Stock Down 1.1 %

Shares of ABSI traded down $0.04 on Thursday, hitting $3.04. The company's stock had a trading volume of 640,877 shares, compared to its average volume of 2,575,282. The firm's fifty day moving average price is $3.04 and its 200-day moving average price is $3.44. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. Absci Co. has a fifty-two week low of $2.01 and a fifty-two week high of $6.33. The firm has a market capitalization of $386.52 million, a price-to-earnings ratio of -3.26 and a beta of 2.22.

Absci (NASDAQ:ABSI - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.03). The company had revenue of $0.67 million during the quarter, compared to the consensus estimate of $1.77 million. Absci had a negative net margin of 2,321.56% and a negative return on equity of 46.56%. On average, equities research analysts expect that Absci Co. will post -0.89 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ABSI shares. Guggenheim restated a "buy" rating and issued a $10.00 target price on shares of Absci in a research note on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Absci in a report on Wednesday, March 19th. Needham & Company LLC reiterated a "buy" rating and set a $9.00 target price on shares of Absci in a research report on Wednesday, April 9th. Finally, KeyCorp increased their price target on shares of Absci from $5.00 to $9.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $8.40.

Absci Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.